Meal planning site ‘Eat This Much’ plays part of virtual nutritionist

Meal planning site ‘Eat This Much’ plays part of virtual nutritionist - The Washington Post wpostServer: http://css.washingtonpost.com/wpost Real Estate Rentals Cars Today's PaperGoing Out GuideFind&SaveService AlleyHome PostTVIn PostTVPoliticsIn PoliticsCongressCourts & LawThe Fed PageHealth CarePollingWhite HouseGovBeatMd. PoliticsVa. PoliticsD.C. PoliticsBlogs & Columns

Senators strike deal on wording...
Post Politics | Ed O'KeefeNorth Carolina GOP split on immigration
GovBeat | Reid WilsonDiana Nyad: Dream
She The People | Diana ReeseWhy Mitch McConnell’s not...
The Fix | Sean SullivanOpinionsIn OpinionsToles CartoonsTelnaes AnimationsThe Post's ViewLeft-LeaningRight-LeaningLocal OpinionsColumnist IndexFeatured Blogs

Dear Dennis Rodman, I will be your...
ComPost | Alexandra PetriHappy Hour Roundup
The Plum Line | Greg SargentBill de Blasio jumps past 40 percent
PostPartisan | Jonathan CapehartPro-Israel groups rally for Syria...
Right Turn | Jennifer RubinLocalIn LocalD.C.MarylandVirginiaCrimeEducationObituariesTransportationWeatherBlogs & ColumnsBlogs & Columns

Wonderful Wednesday, fabulous Friday...
Capital Weather Gang | Dan StillmanKeep the summer alive with tiki...
Going Out Guide | Fritz HahnAll lanes of I-95 South closed...
Dr. Gridlock | Maggie Fazeli FardSportsIn SportsRedskins/NFLCapitals/NHLWizards/NBANationals/MLBD.C.United/SoccerCollegesAllMetSportsBlogs & ColumnsForumsOtherSportsBlogs & Columns

Rookie camp roster
Capitals Insider | Katie CarreraPSL: Redskins predictions and Bryce...
DC Sports Bog | Mitch RubinRedskins vs. Eagles start time...
The Insider | Mike JonesRamos playing every day
Nationals Journal | Adam KilgoreNationalIn NationalEnergy &EnvironmentHealth & ScienceEducationNational SecurityInvestigationsOn FaithOn LeadershipInnovationsOn GivingCorrectionsBlogs & Columns

Graduates with high GMAT scores...
Innovations | Vivek WadhwaHiring tips for federal leaders
On Leadership | Tom FoxPope Francis pleads for peace in...
On Faith | Elizabeth TenetyWorldIn WorldAfricaTheAmericasAsia &PacificEuropeMiddle EastNational SecurityWar ZonesSpecial ReportsColumns & BlogsBlogs & Columns

The 11 questions Congress faces...
WorldViews | Max FisherTeju Cole's 9 questions about Britain
WorldViews | Max FisherShould the U.S. strike Syria?
WorldViews | Max FisherInterview with Syrian war photographer
WorldViews | Max FisherBusinessIn BusinessEconomyIndustriesLocal BusinessMarketsPolicy&RegulationTechnologyWorldBusinessCapital BusinessOn Small BusinessOn I.T.Blogs & Columns

Long-term, who will take care of...
The Color of Money | Michelle SingletaryThe best sentences we read today
Wonkblog | Brad PlumerTechIn TechnologyPolicyInnovationGreenTechnologyThe SwitchPhotoGalleriesBlogs & Columns

Uber picks up three top execs from...
Hayley TsukayamaBirds: Nature's drones?
The Switch | Andrea PetersonHow the U.S. provides tech support...
The Switch | Andrea PetersonIs Nokia about to become a patent...
The Switch | Brian FungLifestyleIn LifestyleAdviceCarolyn HaxFoodHome & GardenStyleTravelWeddingsWellnessMagazineKidsPostOn ParentingBlogs & Columns

'American Idol' finally makes it...
The Style Blog | Emily YahrWizards' John Wall buys Potomac...
The Reliable Source | The Reliable SourceEntertainmentIn EntertainmentBooksComicsGoing Out GuideHoroscopesMoviesMuseumsMusicPuzzles & GamesTheater &DanceTVBlogs & Columns

Mort Walker at 90: ‘Beetle...
Comic Riffs | Michael CavnaKeep the summer alive with tiki...
Going Out Guide | Fritz HahnJobsIn Jobs#header-v3 #main-nav li.realestate{display:none;}#header-v3 #main-nav li a.top, #header-v3 #main-nav li a.top:link, #header-v3 #main-nav li a.top:visited, #header-v3 #main-nav li a.top:hover {font-size:13px;padding: 0 4px 0 5px !important;}#header-v3 #main-nav li a.home, #header-v3 #main-nav li a.home:link, #header-v3 #main-nav li a.home:visited, #header-v3 #main-nav li a.home:hover {padding: 0px !important;}#header-v3 #main-nav li.politics {border-left:none;}#header-v3 #main-nav li.classifieds {border-right:none;}#header-v3 #main-nav-wrapper-v2 .classifieds .rollMe {right:-1px;height:155px;width:260px;}#header-v3 #main-nav li.politics:hover {-moz-box-shadow: none;-webkit-box-shadow: none;box-shadow: none;}MoreClassifiedsCarsDealsReal EstateRentalsPhotosBlogsDiscussionsFind&SaveObituariesArchivesTopicsWP Wine ClubService Alley Wellness In the NewsCarolyn Hax Susan Burke Jeff Bezos Seth Goldman David Frost ???initialComments:true! pubdate:09/03/2013 17:16 EDT! commentPeriod:14! commentEndDate:9/17/13 5:16 EDT! currentDate:9/3/13 8:0 EDT! allowComments:true! displayComments:true!‘Fifty Shades of Grey’ cast

Katie Couric engaged to John Molner

Venice Film Festival

Teju Cole's 9 questions about Britain

Meal planning site ‘Eat This Much’ plays part of virtual nutritionist

A screen shot of Eat This Much website.

By Maggie Fazeli Fard, E-mail the writer

Two years ago, when Los Angeles’s Louis DeMenthon was trying to bulk up, he encountered the ubiquitous challenge faced by those seeking physique changes: meal planning.

In vain, DeMenthon searched for an online planner that would tell him exactly what foods to eat in order to pack on muscle. When he came up empty-handed, DeMenthon says, “I decided I would just create it myself.”

The Y: Same location, different place Vicky Hallett

The new YMCA Anthony Bowen opens at 14th and W streets NW.

Oh, what a capital Y!

The new YMCA Anthony Bowen — the same location, yet a different place — is opening.

The 23-year-old recently launched Eat This Much, a free meal-planning site that plays the part of a virtual nutritionist.

Based on three simple questions — Do you want to gain or lose weight? How many calories do you need? And how many meals do you want to eat each day? — it spits out a meal plan with nutritional information, recipes, approximate cost and a grocery list.

If, for instance, a user wants to eat 3,000 calories split over five mealtimes, the tool would generate a random assortment of five 600-calorie recipes, such as pork ribs with a side of blueberries or strip steak and kale with caramelized onions and garlic. (Those who don’t know their caloric requirements can use the site’s “Not Sure?” button to calculate their needs based on their starting weight and activity level, and whether they want to lose, gain or maintain.)

Eat This Much also includes options for people who have dietary restrictions or want more control over their plans. Users can choose among low-carb, paleo, Mediterranean, Zone, vegetarian and vegan diet options, and un-check food items that they simply don’t like or are allergic to. DeMenthon plans to have an iPhone app version ready in the next couple months, followed by an Android app.

DeMenthon says it took a bit of trial and error to get Eat This Much, which has more than 20,000 registered users, where it is today.

“The first versions of the app were very simplistic — very bodybuilder-esque. Two chicken breasts for lunch, a tablespoon of peanut butter, a shot of olive oil before bed. .?.?. It was absurd,” he says.

Even the original name — Swole.me — was a nod to bodybuilding culture. But as word spread and popularity grew, DeMenthon was inspired to make improvements that would make the app accessible to more people.

DeMenthon says his app will fill a void in an online dieting sphere dominated by paid weight-loss sites, such as subscription-based WeightWatchers.com and eDiets.com, and free calorie-trackers such as FitDay.com and MyFitnessPal.com, which don’t provide meal plans.

“The hardest part of dieting is knowing where to start,” DeMenthon says. “If you have a plan to follow, it’s easier to meet your goals.”

Reprints$('.infoButton').on( 'mouseenter', function(e){$(this).children().show();} ).on( 'mouseleave' , function(e){$(this).children().hide();} );Discussion Policy | FAQ | About DiscussionsLoading...

Comments

Add your comment  Read what others are sayingAbout Badges SuperFan Badge

SuperFan badge holders consistently post smart, timely comments about Washington area sports and teams.

More about badges | Request a badge

Culture Connoisseur Badge

Culture Connoisseurs consistently offer thought-provoking, timely comments on the arts, lifestyle and entertainment.

More about badges | Request a badge

Fact Checker Badge

Fact Checkers contribute questions, information and facts to The Fact Checker.

More about badges | Request a badge

Washingtologist Badge

Washingtologists consistently post thought-provoking, timely comments on events, communities, and trends in the Washington area.

More about badges | Request a badge

Post Writer Badge

This commenter is a Washington Post editor, reporter or producer.

Post Forum Badge

Post Forum members consistently offer thought-provoking, timely comments on politics, national and international affairs.

More about badges | Request a badge

Weather Watcher Badge

Weather Watchers consistently offer thought-provoking, timely comments on climates and forecasts.

More about badges | Request a badge

World Watcher Badge

World Watchers consistently offer thought-provoking, timely comments on international affairs.

More about badges | Request a badge

Post Contributor Badge

This commenter is a Washington Post contributor. Post contributors aren’t staff, but may write articles or columns. In some cases, contributors are sources or experts quoted in a story.

More about badges | Request a badge

Post Recommended

Washington Post reporters or editors recommend this comment or reader post.

You must be logged in to report a comment.

Sign in here

You must be logged in to recommend a comment.

Sign in here

Comments our editors find particularly useful or relevant are displayed in Top Comments, as are comments by users with these badges: . Replies to those posts appear here, as well as posts by staff writers.

All comments are posted in the All Comments tab.

More about badgesGet a badge

To pause and restart automatic updates, click "Live" or "Paused". If paused, you'll be notified of the number of additional comments that have come in.

Comments our editors find particularly useful or relevant are displayed in Top Comments, as are comments by users with these badges: . Replies to those posts appear here, as well as posts by staff writers. SpamObsceneDuplicate .singular .echo-item-control-Share #newsharebar li .more {left: -565px;top: 10px;} Facebook Twitter Reddit StumbleUpon Digg Delicious Top lifestyle StoriesMost Popular VideosJeffrey Bezos, Washington Post’s next owner, aims for a new ‘golden era’ at the newspaperPaul Farhi 

Long-anticipated new section of SF-Oakland Bay Bridge opens, handles first day’s commutesAssociated Press 

Carolyn Hax: Grandma doesn’t want to play favoritesCarolyn Hax 

Schools try new strategies to battle college drinkingJenna Johnson 

Harry Connick, Jr. and Jennifer Lopez to join Keith Urban on ‘American Idol’ panelMax Ehrenfreund 

Jeffrey P. Bezos visits The Post to meet with editors and othersCraig Timberg 

Ask Amy: Daughter’s food issues are all about controlAmy Dickinson 

Carolyn Hax: When is a crush more than a crush? Carolyn Hax 

Names & Faces: Lance Bass, George Clooney, Beyonce Is the fashion industry at a social crossroads?Robin Givhan 

Charlie Hunnam, Dakota Johnson cast in 'Fifty Shades of Grey' movie -- is this a good idea?Miss Manners: An attempt to be generous leads to embarrassmentMiss Manners 

Miss Manners: Genealogy-mad niece may be greeted as royal painMiss Manners 

Carolyn Hax: Husband’s anxiety, accusations lead wife to question herselfCarolyn Hax 

Teresa Heinz Kerry returns to public after illnessKatie Couric engaged to bankerSpike Gjerde and his Woodberry Kitchen team taking canning to new heights::unspecified:: 

Quoted: Dennis Rodman on his North Korea tripThe kitchen of 2013: Experts dishJura Koncius 

Lawyer leads charge against sexual assault in militaryMelinda Henneberger 

The Post Most: LifestyleMost-viewed stories,videos, and galleries in the past two hours

Most PopularJeffrey Bezos, Washington Post's next owner, aims for a new 'golden era' at the newspaperLong-anticipated new section of SF-Oakland Bay Bridge opens, handles first day's commutesCarolyn Hax: Grandma doesn't want to play favoritesSchools try new strategies to battle college drinkingHarry Connick, Jr. and Jennifer Lopez to join Keith Urban on 'American Idol' panelTop VideosAriel Castro on kidnapping: 'I was driven by sex'Burdette recalls first 9:30 showKerry responds to protesterWho shot this congressman?Jeff Bezos: The newest newspaper manTop GalleriesBurning Man 2013Celebrities who perform for tyrants'American Idol' judges, past and presentBold-face Washington homes'Fifty Shades of Grey' leads to be played by Charlie Hunnam and Dakota Johnson Post Newsletters & Alerts

Sign-up for e-mail newsletters and alerts and get the news you need delivered directly to your inbox.

 Going Out Guide: Dinner & DrinksGoing Out Guide: With The KidsAt HomeDC ScoutGoing Out GuideLean & FitMoviesTravelSee all Washington Post Newsletters

The Washington PostPoliticsOpinionsLocalSportsNationalWorldBusinessTechLifestyleEntertainmentPhotoVideoBlogsClassifieds More ways to get us

Home delivery Mobile & Apps RSS Facebook Twitter Social Reader Newsletter & Alerts Washington Post Live Reprints & Permissions Post Store e-Replica Archive Contact Us

Help & Contact Info Reader Representative Careers Digital Advertising Newspaper Advertising News Service & Syndicate About Us

The Washington Post Company In the community PostPoints Newspaper in Education Digital Publishing Guidelines Partners

Capital Business Capitol Deal El Tiempo Latino Express Find&Save Foreign Policy Washington Post Master Class Parade Magazine Washington Post Tickets The Root Service Alley Slate StudentAdvisor Trove WP Wine Club washingtonpost.com © 1996- The Washington Post Terms of Service Privacy PolicySubmissions and Discussion PolicyRSS Terms of Service Ad Choices Section:/lifestyle/wellness

View the original article here

Biotech: A Scattershot Of Stem Cell Plays Following Yesterday's Bloodbath

(Editors' Note: This article covers micro-cap stocks. Please be aware of the risks associated with these stocks.)

Yesterday, the NASDAQ Biotechnology index (NBI) dropped 3% in reaction to the sell-off in the broader market. Even larger, more stable pharmaceutical companies (those valued at $10B or higher) were down an average of 1.69% by the closing bell. Smaller biotech stocks, valued between $300M-$2B, fared even worse - dropping about 3.23% on average. The pain was experienced across all subsectors of the biotech industry, reflecting the macroeconomic factors that induced yesterday's bearishness.

Stem cell developers, which have been underperformers in 2013, were not spared either despite their recent unpopularity.

This article will discuss some of stem cell companies that were adversely affected by yesterday's trading. We will also identify catalysts that could lead to significant change in the share prices of these companies within the next year.

Pluristem (NASDAQ: PSTI) - This is a rapidly growing and important stem cell company, although it serves as a great example of the unpopularity of stem cell stocks this year. PSTI dropped 5.4% in yesterday's trading on high volume, bringing the stock's YTD performance decisively into the red (-6.6%).

Pluristem grows stem cell lines out of placental stem cells using a special bioreactor designed by the company to create and later harvest what are known as PLX cells. These PLX cells are being studied in a number of disease indications, and can be catered specifically for indications. This includes peripheral artery disease (PAD) indications - critical limb ischemia, and intermittent claudication. PLX cells are also being investigated for muscle injuries.

The stock's most significant near-term upside potential will likely come with progress in the company's trials. One is the big multi-center phase II trial for intermittent claudication, which is currently recruiting patients. This is also going to be a long trial, although completion of enrollment and the promise of interim data next year should spark some interest. Closer in time is the hip repair trial, where PLX cells are expected to improve patient function after 26 weeks. This should provide multiple data-based catalysts throughout 2014.

Neuralstem (NASDAQ: CUR) - the popularity of this stem cell company is increasing this year, along with its valuation. Within the last year, CUR has moved from $.52/share to yesterday's closing price of $1.62/share - a gain of ~212%. Yesterday, Neuralstem dropped 4.14% to $1.62/share - roughly 17% off its 52-week high of $1.96/share.

A number of things have pushed Neuralstem higher this year, although the majority of the credit should be given to the finalized Phase I data that the company presented at The American Association of Neurological Surgeons Annual Meeting in late April (link). This was an early stage trial that tested the company's line of stem cells - NSI-566 - in patients with Lou Gehrig's disease/ALS (Amytrophic Lateral Sclerosis).

The results of a Phase I trial were discussed in further detail in this note, from May 21st 2013 (link):

"The trial, which was conducted on 15 patients with ALS, started in early 2010 and concluded only recently. According to PI Eva Feldman in a recent Neuralstem press release, 6 of the patients in the study experienced stability, slow progression, or even improved disease course 700 to 850 days after implantation with NSI-566 cells. The remaining 9 saw no noticeable improvements, while 6 patients died of ALS within the first few months after the surgery."

Although early stage, the data were very encouraging and seem to allow CUR to stay comfortably in the $1.40-1.70 range. The Phase II ALS trial is undergoing enrollment now, and could provide early data in H1 of next year to potentially induce another rally. A safety study (Phase I) for NSI-566 in the spinal cord injury indication was also approved and will start enrolling in the near future.

Brainstorm Cell Therapeutics (BCLI.OB) - this Israeli stem cell company has been relatively quiet, although activity is beginning to pick up after a recent public offering. BCLI dropped 2.5% in yesterday's trading, and is currently ~28% off its 52-week highs of .27/share.

In July, the company received orphan drug designation in the European Union for NurOwn in the treatment of ALS (Amytrophic Lateral Sclerosis) (link), and has made significant progress in its 12 patient Phase IIa dose-escalation trial at the Hadassah Medical Center in Israel. The most recent group was treated with a 50% higher dose of NurOwn cells relative to the previous, which should allow the company to better calibrate its dosing for the upcoming US Phase II trial.

The company held a conference call on August 14th to discuss its status, although new details on the Israeli trial were not given for legal reasons. It was confirmed that the company's recent raise should be sufficient to set up larger Phase II trials in the US. The company does have to finish its IND application for NurOwn, although this expected to finish quite smoothly due to the prior approval of other stem cell treatments of ALS (specifically NSI-566).

Brainstorm is significantly cheaper than its peers in terms of valuation, likely because of the uncertainty surrounding this company and its status as a more "foreign" company. This could change once the company makes a bigger presence in the United States with Phase II development.

BioTime (NYSE: BTX) - this complicated "multi-purpose" cell company erased a substantial chunk of its gains with a 5.50% drop yesterday.

The company is comprised of 9 subsidiary companies based in four different countries, and may be best known for its acquisition of Geron's former stem cell assets. Most of its potential is locked in early-stage development programs, although the company already generates some revenues through the sale of research products and stem cells.

BTX could see significant movement in reaction to upcoming catalysts that could add significantly to the underlying value of the company. After years of development, the company is close to launching a cell delivery device known as HyStem-Rx, which aims to deliver stem cells in a manner that wouldn't kill them soon after injection. Hystem is scheduled for introduction into Europe through CE marking (it is a device) - possibly as early as 2014.

Stem Cells Inc. (NASDAQ: STEM) - STEM has managed to hold its ground throughout the year, although it is back to square one after yesterday's 2.38% drop. The company grew a line of neural stem cells derived from brain tissue designated as HuCNS-SC. These cells are being developed for a variety of neuron-related disorders, with the most mature development programs currently being in spinal cord injury and Pelizaeus-Merzbacher Disease (PMD). The company can also sell cells to generate side revenues.

Upcoming events for STEM include the continuation and eventual completion of enrollment into the Phase I/II spinal cord injury trial, which has just been expanded into Canada. This trial will look for minor improvements in an expected total of 12 patients recovering 3-12 months after spinal cord injuries, and may have interim data to present soon.

Investors should also look for development in PMD patients that the company is following (link). There should also be much greater investor excitement for the recently initiated Alzheimer's disease program due to the sheer size of that indication and the preclinical data in support of HuCNS-SC.

Notes on Biotech Risk:

Investors should realize that unprofitable biotechnology companies in the development stage experience particularly high volatility, are speculative, and do hold significant risk for loss of wealth. Investors believe that the company's valuation will increase more over time than the rate at which the company will burn cash, which is why the high risks are taken.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. (More...)

How would you like your alerts on   delivered?

Added to your bookmarks on the Seeking Alpha homepage

new SA.Pages.Article.bookmark("_bottom");

View the original article here

Small protein plays big role in asthma severity

Main Category: Respiratory / Asthma
Also Included In: Immune System / Vaccines;  Ear, Nose and Throat
Article Date: 05 Aug 2013 - 1:00 PDT Current ratings for:
Small protein plays big role in asthma severity

A new culprit has been identified that likely plays a big role in the severity of asthma - a small protein chemokine called CCL26. These findings were published in the Journal of Leukocyte Biology and represent the first demonstration that CCL26 is a potent regulator of the migration of asthmatic eosinophils, commonly observed in asthmatic airways. Results from this discovery may lead to new drug targets for the treatment of asthma.

"We hope that these studies will help to develop a new treatment that would specifically abrogate bronchial inflammation and provide a specific, efficacious and well-tolerated alternative to the current therapy," said Michel Laviolette, M.D., a researcher involved in the work from the Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Faculté de Médecine, Université Laval, Québec, Canada.

Specifically, data from the report suggest that the chemokine CCL26 plays a crucial role in asthma pathogenesis and its severity by supporting the recruitment of eosinophils early in the development of the disease, and possibly later in severe asthma associated with persisting lung eosinophilia. To make this discovery, scientists used blood from healthy and asthmatic subjects to isolate eosinophils and measure their migration response to CCL26 in vitro. Researchers also assessed their response to other chemokines, CCL11 and CCL24, and showed that only CCL26 induced an amplified eosinophil migration of asthmatic eosinophils compared to healthy cells. Interestingly, this additional migration occurred after a 6-hour incubation and, in contrast to the migration induced by the other chemokines, was not eradicated by blocking the chemokine receptor CCR3 shared by these three chemokines.

"The control of eosinophils is central to asthmatic diseases and the underlying mechanisms are prime targets for treatments for the debilitating and sometimes life-threatening symptoms of asthma and allergy," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "This report shows that CCL26 could be a novel drug target to regulate eosinophils in these diseases."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our respiratory / asthma section for the latest news on this subject.

The Journal of Leukocyte Biology publishes peer-reviewed manuscripts on original investigations focusing on the cellular and molecular biology of leukocytes and on the origins, the developmental biology, biochemistry and functions of granulocytes, lymphocytes, mononuclear phagocytes and other cells involved in host defense and inflammation. The Journal of Leukocyte Biology is published by the Society for Leukocyte Biology.

Details: Véronique Provost, Marie-Chantal Larose, Anick Langlois, Marek Rola-Pleszczynski, Nicolas Flamand, and Michel Laviolette. CCL26/eotaxin-3 is more effective to induce the migration of eosinophils of asthmatics than CCL11/eotaxin-1 and CCL24/eotaxin-2. J Leukoc Biol August 2013 94:213-222; doi:10.1189/jlb.0212074;

Federation of American Societies for Experimental Biology

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Federation of American Societies for Experimental. "Small protein plays big role in asthma severity." Medical News Today. MediLexicon, Intl., 5 Aug. 2013. Web.
5 Aug. 2013. APA

Please note: If no author information is provided, the source is cited instead.

'Small protein plays big role in asthma severity'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here